Pharsight

Bevyxxa is owned by Portola Pharms Inc.

Bevyxxa contains Betrixaban.

Bevyxxa has a total of 5 drug patents out of which 0 drug patents have expired.

Bevyxxa was authorised for market use on 23 June, 2017.

Bevyxxa is available in capsule;oral dosage forms.

Bevyxxa can be used as prophylaxis of deep vein thrombosis (dvt); prophylaxis of venous thrombosis, prophylaxis of pulmonary embolism, inhibiting coagulation.

Drug patent challenges can be filed against Bevyxxa from June, 2021.

The generics of Bevyxxa are possible to be released after 29 March, 2031.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598276	PORTOLA PHARMS INC	Pharmaceutical salts and polymorphs of a factor Xa inhibitor	Nov, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555023	PORTOLA PHARMS INC	Pharmaceutical salts and polymorphs of a factor Xa inhibitor	Nov, 2026 (3 years from now)
US8557852	PORTOLA PHARMS INC	Methods of using crystalline forms of a salt of a factor Xa inhibitor	Sep, 2028 (5 years from now)
US8987463	PORTOLA PHARMS INC	Methods of synthesizing factor Xa inhibitors	Dec, 2030 (7 years from now)
US8404724	PORTOLA PHARMS INC	Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor	Mar, 2031 (8 years from now)